160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)

A Schneeweiss,V Möbus,H Tesch,P Klare,C Denkert,K Kast,C Hanusch,T Link,M Untch,C Jackisch,J-U Blohmer,P.A Fasching,C Solbach,J Huober,K.E Rhiem,V Nekljudova,K Lübbe,S Loibl

doi:10.1016/j.annonc.2020.08.282

Abstract

160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)

Full Text